Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI), 27248 [2020-09701]
Download as PDF
<![CDATA[
27248
Federal Register / Vol. 85, No. 89 / Thursday, May 7, 2020 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–643]
Importer of Controlled Substances
Application: Almac Clinical Services
Incorp. (ACSI)
ACTION:
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
DEPARTMENT OF JUSTICE
In
accordance with 21 CFR 1301.34(a), this
is notice that on April 10, 2020, Almac
Clinical Services Incorp. (ACSI), 25
Fretz Road, Souderton, Pennsylvania
18964, applied to be registered as an
importer of the following basic class(es)
of a controlled substance:
Bulk Manufacturer of Controlled
Substances Application: Alcami
Wisconsin Corporation
SUPPLEMENTARY INFORMATION:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before June 8, 2020. Such persons
may also file a written request for a
hearing on the application on or before
June 8, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
DATES:
Controlled substance
Drug
code
Schedule
Noroxymorphone ......
9668
II
The company plans to import the
listed controlled substance in dosage
form to conduct clinical trials.
William T. McDermott,
Assistant Administrator.
Drug Enforcement Administration
[Docket No. DEA–639]
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 6, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on March 13, 2020, Alcami
Wisconsin Corporation, W130N10497
Washington Drive, Germantown,
Wisconsin 53022–4448, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substances:
SUPPLEMENTARY INFORMATION:
[FR Doc. 2020–09701 Filed 5–6–20; 8:45 am]
BILLING CODE 4410–09–P
Controlled substance
Drug code
Marihuana Extract ...........................................................................................................................................................
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
5-Methoxy-N-N-dimethyltryptamine .................................................................................................................................
Thebaine ..........................................................................................................................................................................
Alfentanil ..........................................................................................................................................................................
The company plans to provide bulk
active pharmaceutical ingredient to
support clinical trials. In reference to
drug codes 7350 Marihuana extract,
7360 Marihuana, and 7370
Tetrahydrocannabinols, the company
plans to manufacture these substances
synthetically. No other activities for
these drug codes are authorized for this
registration.
DEPARTMENT OF JUSTICE
William T. McDermott,
Assistant Administrator.
DATES:
[FR Doc. 2020–09702 Filed 5–6–20; 8:45 am]
khammond on DSKJM1Z7X2PROD with NOTICES
BILLING CODE 4410–09–P
VerDate Sep<11>2014
16:45 May 06, 2020
Jkt 250001
Drug Enforcement Administration
[Docket No. DEA–641]
Importer of Controlled Substances
Application: AndersonBrecon Inc. dba
PCI of Illinois
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before June 8, 2020. Such persons
may also file a written request for a
hearing on the application on or before
June 8, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
7350
7360
7370
7431
9333
9737
Schedule
I
I
I
I
II
II
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on March 20, 2020,
AndersonBrecon Inc. dba PCI of Illinois,
5775 Logistics Parkway, Rockford,
Illinois 61109–3608, applied to be
registered as an importer of the
following basic class(es) of a controlled
substance:
SUPPLEMENTARY INFORMATION:
E:\FR\FM\07MYN1.SGM
07MYN1
]]>Agencies
[Federal Register Volume 85, Number 89 (Thursday, May 7, 2020)]
[Notices]
[Page 27248]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09701]
[[Page 27248]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-643]
Importer of Controlled Substances Application: Almac Clinical
Services Incorp. (ACSI)
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before June 8, 2020.
Such persons may also file a written request for a hearing on the
application on or before June 8, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on April 10, 2020, Almac Clinical Services Incorp.
(ACSI), 25 Fretz Road, Souderton, Pennsylvania 18964, applied to be
registered as an importer of the following basic class(es) of a
controlled substance:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Noroxymorphone....................... 9668 II
------------------------------------------------------------------------
The company plans to import the listed controlled substance in
dosage form to conduct clinical trials.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-09701 Filed 5-6-20; 8:45 am]
BILLING CODE 4410-09-P
